Manufacturer
Janssen
Contents
Doxorubicin HCl
Indication
Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS), in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm3) & extensive mucocutaneous or visceral disease. 1st-line systemic or 2nd-line chemotherapy in AIDS-KS patient w/ disease that progressed w/ or in patients intolerant to, prior combination systemic chemotherapy comprising of at least 2 of the following: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). In combination w/ bortezomib for the treatment of progressive multiple myeloma in patients who have received at least 1 prior to therapy & who have already undergone, or unsuitable for, bone marrow transplant.
Instruction
Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin HCl.Caelyx should only be administered under the supervision of a qualified oncologist specialized in the administration of cytotoxic agents.Caelyx is for single-use IV administration only.
Drug interaction
Other cytotoxic agents especially myelotoxic agents.
Malaysia
